GlassScriptPhysician profile
William J Walsh
NPI 1730374604
$3,276.11
in general payments reported to CMS, 2019-2025
28 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what 91% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
See the full distribution for Addiction Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.53 · 2021: $239 · 2023: $235 · 2024: $1,191 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Consulting Fee: $303 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,606.08 |
| Consulting Fee | $303.33 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $542.50 | 2021-2024 | |
| Indivior INC. | $454.86 | 2019-2025 | Sublocade |
| Novo Nordisk INC | $273.48 | 2024-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $232.49 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Corcept Therapeutics | $206.77 | 2024-2025 | Korlym |
| Edwards Lifesciences Corporation | $202.44 | 2025 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $166.58 | 2023-2025 | Breztri, Airsupra |
| Astellas Pharma US INC | $161.05 | 2024-2025 | Veozah |
| Lilly USA, LLC | $133.45 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Phathom Pharmaceuticals, INC. | $124.99 | 2025 | Voquezna |
| Abbvie INC. | $121.09 | 2024-2025 | |
| Boston Scientific Corporation | $110.38 | 2024-2025 | Watchman Flx, Wavewriter Alpha Prime 16 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.86 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $83.52 | 2024-2025 | Inspire |
| Alkermes, INC. | $73.10 | 2024 | Vivitrol |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.79 | 2023 | Verquvo |
| Pfizer INC. | $43.43 | 2023-2024 | |
| Davol INC. | $39.44 | 2025 | Phasix Mesh |
| Braeburn INC. | $28.30 | 2025 | Brixadi |
| Lundbeck LLC | $24.74 | 2025 | Rexulti |
| Seqirus USA INC | $18.83 | 2025 | Fluad, Flucelvax |
| Cranial Technologies, INC | $16.69 | 2024 | Doc Band |
| Neurelis, INC. | $15.32 | 2024 | Valtoco |
| Exeltis, USA INC. | $14.75 | 2025 | Slynd |
| Takeda Pharmaceuticals U.S.A., INC. | $13.26 | 2024 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.